ALK1 belongs to the type I receptor family for transforming growth factor-␤ family ligands. Heterozygous ALK1 mutations cause hereditary hemorrhagic telangiectasia type 2 (HHT2), a multisystemic vascular disorder. Based largely on in vitro studies, TGF-␤1 has been considered as the most likely ALK1 ligand related to HHT, yet the identity of the physiologic ALK1 ligand remains controversial. In cultured endothelial cells, ALK1 and another TGF-␤ type I receptor, ALK5, regulate angiogenesis by controlling TGF-␤ signal transduction, and ALK5 is required for ALK1 signaling. However, the extent to which such interactions between these 2 receptors play a role in pathogenesis of HHT is unknown. We directly addressed these issues in vivo by comparing the phenotypes of mice in which the Alk1, Alk5, or Tgfbr2 gene was conditionally deleted in restricted vascular endothelia using a novel endothelial Cre transgenic line. Alk1-conditional deletion resulted in severe vascular malformations mimicking all pathologic features of HHT. Yet IntroductionHereditary hemorrhagic telangiectasia (HHT) is an autosomaldominant vascular disorder characterized by recurrent nosebleeds, mucocutaneous telangiectases, and arteriovenous malformations (AVMs) in the brain, lungs, liver, and gastrointestinal tract. 1,2 It has been shown that heterozygous mutations in ENDOGLIN (ENG) and Activin receptor-like kinase 1 (ALK1) cause HHT1 and HHT2, respectively. 2-4 Both of these genes are expressed predominantly in endothelial cells. 5,6 Because ENG and ALK1 are transforming growth factor-␤ (TGF-␤) type III and type I receptors, respectively, it has been postulated that HHT is caused by impaired signaling of a common TGF-␤ family ligand that interacts with these 2 receptors. Recent finding of mutations in the common downstream mediator of TGF-␤ family signals, SMAD4, in a subset of HHT patients also support this hypothesis. 7 Despite the identification of these genes responsible for HHT, the underlying mechanisms for the pathogenesis of HHT remain obscure. One of the chief contributing factors underlying this obscurity is the complexity of the transduction pathway of ENG, ALK1, and SMAD4. The TGF-␤ superfamily consists of more than 40 ligands that can be classified into several subfamilies, including TGF-␤, Activin, and bone morphogenetic protein (BMP). 8 TGF-␤ family cytokines exert their effects by binding to heteromeric complexes of 2 types of transmembrane serine/threonine kinase receptors. 9 The type II receptors function primarily as the binding receptors. On binding their ligand(s), type II receptors associate with and phosphorylate the type I receptors, which in turn activate downstream SMAD proteins. Each TGF-␤ ligand interacts with one or more type II and type I receptors, but TGFBR2 is the only type II receptor that has been shown to interact with TGF-␤ subfamily ligands (TGF-␤1, -␤2, and -␤3).ENG can interact with multiple TGF-␤ family members, such as TGF-␤1/␤3, Activin-A, BMP2, and BMP7, in the presence of a suitable ligand-binding type II...

The NAD-dependent histone deacetylase Sir2 plays a key role in connecting cellular metabolism with gene silencing and aging. The androgen receptor (AR) is a ligand-regulated modular nuclear receptor governing prostate cancer cellular proliferation, differentiation, and apoptosis in response to androgens, including dihydrotestosterone (DHT). Here, SIRT1 antagonists induce endogenous AR expression and enhance DHTmediated AR expression. SIRT1 binds and deacetylates the AR at a conserved lysine motif. Human SIRT1 (hSIRT1) repression of DHT-induced AR signaling requires the NAD-dependent catalytic function of hSIRT1 and the AR lysine residues deacetylated by SIRT1. SIRT1 inhibited coactivator-induced interactions between the AR amino and carboxyl termini. DHT-induced prostate cancer cellular contact-independent growth is also blocked by SIRT1, providing a direct functional link between the AR, which is a critical determinant of progression of human prostate cancer, and the sirtuins.

The transdermal route of administration provides numerous advantages over conventional routes i.e., oral or injectable for the treatment of different diseases and cosmetics applications. The skin also works as a reservoir, thus deliver the penetrated drug for more extended periods in a sustained manner. It reduces toxicity and local irritation due to multiple sites for absorption and owes the option of avoiding systemic side effects. However, the transdermal route of delivery for many drugs is limited since very few drugs can be delivered at a viable rate using this route. The stratum corneum of skin works as an effective barrier, limiting most drugs’ penetration posing difficulty to cross through the skin. Fortunately, some non-invasive methods can significantly enhance the penetration of drugs through this barrier. The use of nanocarriers for increasing the range of available drugs for the transdermal delivery has emerged as a valuable and exciting alternative. Both the lipophilic and hydrophilic drugs can be delivered via a range of nanocarriers through the stratum corneum with the possibility of having local or systemic effects to treat various diseases. In this review, the skin structure and major obstacle for transdermal drug delivery, different nanocarriers used for transdermal delivery, i.e., nanoparticles, ethosomes, dendrimers, liposomes, etc., have been discussed. Some recent examples of the combination of nanocarrier and physical methods, including iontophoresis, ultrasound, laser, and microneedles, have also been discussed for improving the therapeutic efficacy of transdermal drugs. Limitations and future perspectives of nanocarriers for transdermal drug delivery have been summarized at the end of this manuscript.

Cyclin D1 encodes a regulatory subunit, which with its cyclin-dependent kinase (Cdk)-binding partner forms a holoenzyme that phosphorylates and inactivates the retinoblastoma protein. In addition to its Cdk binding-dependent functions, cyclin D1 regulates cellular differentiation in part by modifying several transcription factors and nuclear receptors. The molecular mechanism through which cyclin D1 regulates the function of transcription factors involved in cellular differentiation remains to be clarified. The histone acetyltransferase protein p300 is a co-integrator required for regulation of multiple transcription factors. Here we show that cyclin D1 physically interacts with p300 and represses p300 transactivation. We demonstrated further that the interaction of the two proteins occurs at the peroxisome proliferator-activated receptor ␥-responsive element of the lipoprotein lipase promoter in the context of the local chromatin structure. We have mapped the domains in p300 and cyclin D1 involved in this interaction. The bromo domain and cysteine-and histidine-rich domains of p300 were required for repression by cyclin D1. Cyclin D1 repression of p300 was independent of the Cdkand retinoblastoma protein-binding domains of cyclin D1. Cyclin D1 inhibits histone acetyltransferase activity of p300 in vitro. Microarray analysis identified a signature of genes repressed by cyclin D1 and induced by p300 that promotes cellular differentiation and induces cell cycle arrest. Together, our results suggest that cyclin D1 plays an important role in cellular proliferation and differentiation through regulation of p300.The cyclins and the associated cyclin-dependent kinases (Cdks) 1 govern proliferation of mammalian cells. The regulatory subunit cyclin binds and activates their catalytic partners, or Cdks, allowing phosphorylation of a series of critical cellular substrates, thereby promoting cell cycle progression (1). D-type cyclins fluctuate in abundance during cell cycle progression, induced by mitogenic stimulation, and in the case of cyclin D1 serve as a key target in oncogenic and mitogenic signaling. Phosphorylation of pRb in normal cells by cyclin D/Cdk4/6 is thought to induce structural changes of pRb and in turn allow sequential phosphorylation by cyclin E/Cdk2 and cyclin A/Cdk2 (2, 3). Cyclin D-Cdk complexes associate with several other proteins, including cell cycle inhibitors of the p27 KIP1 and p21 CIP1 family to regulate the functional activity of these inhibitors in trans (1). Clinical observations have identified cyclin D1 overexpression as a frequent occurrence in human breast tumors, lymphomas, and several other tumor types. Molecular genetic analysis of cyclin D1 function in the mouse demonstrates an essential role for cyclin D1 in normal mammary gland development and nonredundant functions for the D-type cyclins in hematopoietic stem cell expansion (4). The terminal alveolar breast bud developmental defect in cyclin D1-deficient mice was recapitulated by deficiency of either IKK␣, mutation of Nik (Aly) ...